Patents Examined by Jegatheesan Seharaseyon
  • Therapeutic effect of oral interferon a administration on chronic intractable external otitis
    Patent number: 10799448
    Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 13, 2020
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTD
    Inventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10787508
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 29, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Use of interleukin-22 in the treatment of fatty liver disease
    Patent number: 10786551
    Abstract: The present invention relates to use of interleukin-22 (IL-22) for treating fatty liver disease by decreasing the levels of transaminases. The use of IL-22 in decreasing the levels of transaminases is also provided.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: September 29, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yu Liang Huang, Zhi Hua Huang, Qi Sun
  • Immunoglobulins and uses thereof
    Patent number: 10787495
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Antibodies to TGF-?
    Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Anti-TNF?-antibodies and functional fragments thereof
    Patent number: 10774140
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 15, 2020
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Anti-TNF-alpha-antibodies and functional fragments thereof
    Patent number: 10759852
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: September 1, 2020
    Assignee: Numab Innovation AG
    Inventors: Tea Gunde, Sebastian Meyer
  • Interferon alpha and omega antibody antagonists
    Patent number: 10759854
    Abstract: The present invention relates to antibodies that broady neutralize interferon-? and interferon-?, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 1, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Judith Connor, Chichi Huang, Jarrat Jordan, Xiefan Lin-Schmidt, Jinquan Luo, Lu Lu, Christian Martinez, Galina Obmolova, Ronald Swanson
  • Anti-CD25 antibody agents
    Patent number: 10752691
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 25, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • IL-26 inhibitors
    Patent number: 10751416
    Abstract: The present invention relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with interleukin 26 (IL-26), including inflammatory diseases, such as psoriasis and/or bacterial infections.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 25, 2020
    Assignees: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV), BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Michel Gilliet, Jeremy Di Domizio, Stephan Meller
  • Anti-CD25 antibody agents
    Patent number: 10745485
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 18, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Anti-CD25 antibody agents
    Patent number: 10738125
    Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 11, 2020
    Assignees: Tusk Therapeutics Ltd., Cancer Research Technology Limited
    Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
  • Interferon-beta analog peptide
    Patent number: 10738097
    Abstract: An interferon-beta (IFN?) analog peptide including a plurality of amino acid substitutions in an amino acid sequence of IFN? as set forth in SEQ ID No. 4. The IFN? analog peptide may include a plurality of amino acid substitution in the amino acid sequence of IFN? in at least one position of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 18, 19, 20, 21, 22, 23, 24, and combinations thereof, numbered in accordance with SEQ ID No. 4.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: August 11, 2020
    Inventors: Mansour Poorebrahim, Matin Asghari, Mohammad Hossein Nasr-Esfahani, Nima Sanadgol, Mohammad Foad Abazari, Maryam Nouri Aleagha, Hassan Askari, Solmaz Sadeghi
  • Use of M-CSF for preventing or treating myeloid cytopenia and related complications
    Patent number: 10709762
    Abstract: The invention relates to methods and compositions comprising a macrophage colony stimulating factor (M-CSF) polypeptide or an agonist of the M-CSF receptor for preventing or treating myeloid cytopenia and related complications (such as infections) in a patient in need thereof (such as a patient undergoing hematopoietic stem cell transplantation).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: July 14, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE
    Inventor: Michael Sieweke
  • Methods of identifying and treating subjects having acute respiratory distress syndrome
    Patent number: 10689703
    Abstract: The present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: June 23, 2020
    Assignee: National Jewish Health
    Inventors: Jerry A. Nick, Kenneth C. Malcolm
  • Methods and compositions for modulating T-GM cell function
    Patent number: 10690666
    Abstract: Disclosed herein is a T-helper cell (“TH-GM” cell) that is regulated by IL-7/STAT5 and which secrete GM-CSF/IL-3. Also disclosed are methods and compositions for modulating TH-GM function for the treatment of, e.g., inflammatory disorders. Diagnostic and prognostic methods for specifically identifying TH-GM-mediated inflammatory disorders (e.g., rheumatoid arthritis), as distinct from and/or in addition to non-TH-GM-mediated (e.g., TNF-?-mediated) inflammatory disorders, are also provided.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 23, 2020
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Fu Xin-Yuan, Wanqiang Sheng, Yongliang Zhang, Fan Yang
  • Mono- and di-PEG IL-10 production; and uses
    Patent number: 10639353
    Abstract: Provided are methods of producing mono- and di-pegylated IL-10.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 5, 2020
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Steven J. Blaisdell, Collette M. Cutler, Brittany C. Paporello, Alexandre Ambrogelly
  • Reactive oxygen species production by myeloid-derived suppressor cells as a predictor of patient response to interferon-? therapy
    Patent number: 10627403
    Abstract: The present invention relates to methods and materials for more effectively treating patients with interferon. It is based on the discovery that clinical response to interferon (IFN) therapy is mediated in part by inhibition of activation of MDSC and such inhibition can be observed after a test dose of interferon; a significant decrease of reactive oxygen species (ROS) production by MDSC (as a measure of their activation) after IFN therapy is predictive of overall response to immunotherapy in cancer patients.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa Geskin, Oleg E. Akilov
  • Immune function development promoter and growth promoter
    Patent number: 10590180
    Abstract: The present invention discloses immune function development promoters and growth promoters comprising CCL25. The development of immune functions in a subject can be promoted by ingesting an immune function development promoter according to the present invention. Moreover, growth of a subject can be promoted by ingesting a growth promoter according to the present invention.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: March 17, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY
    Inventor: Kazutoshi Sayama
  • GM-CSF variants and methods of use
    Patent number: 10562948
    Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 18, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler